Insider Purchases: Inside the Buy
Tag: Funanc1al Investing
Can V.F. Corporation Face North and Land More Than Timber?
Insiders are buying, the CEO’s betting big, and the stitches are finally tightening at V.F. Corp. With a turnaround in motion and brands like Vans and Timberland in the mix, could this stock step back into fashion?
Penn Entertainment: A Double-Down That’s Finally Paying Off?
Penn Entertainment ($PENN) is showing signs of life — insiders are doubling down, revenues are climbing, and digital bets are growing fast. With shares rebounding, is it time to follow the high-rollers or step back from the table? 🎰📈
Middleby: Insiders Are Buying Like Something’s Cooking (and Not Just in the Kitchen…)
Insiders are grabbing shares of Middleby like fresh-baked cookies—$93M worth in May alone. With buybacks, spinoffs, and top-tier equipment across commercial, residential, and food processing, this stock may be more than a kitchen story. Is it time to take a bite?
Repay Holdings: Time to Reward the Patient Holder?
Insider buying is heating up at Repay Holdings. With over 200 institutions on board and a bargain-bin valuation, this fintech underdog might be getting ready to repay patient investors—with upside.
Ligand Pharmaceuticals (LGND): In a League of Its Own? Insiders Think So!
Ligand Pharma (LGND) isn’t chasing moonshots—it’s collecting royalties across a sprawling biotech empire. With both the CEO and CFO buying in, and a royalty engine showing 46% revenue growth, insiders may know something. Is this the most compelling quiet biotech turnaround on the Nasdaq?
🔬 Illumina (ILMN): Let’s Illuminate the Bull Case!
After losing nearly 80% of its value since 2021, Illumina (ILMN) may be ready for a glow-up. CEO Jacob Thaysen and CFO Ankur Dhingra just bought big, and institutional holders are still hanging on. What do they see—and should you see it too?
🏠 Douglas Elliman (DOUG): Luxury Real Estate, Budget Stock Price?
Insiders are buying big, the company’s cutting losses, and the cash pile is solid. Douglas Elliman might not be flashy, but it’s not flopping either. A low-priced luxury real estate play worth a look?
🧬 GeneDx (WGS): Profit, Progress, and a 43% Plunge? Sounds Genetic.
GeneDx is profitable. Revenues are growing. Innovation is real. So why did the stock tank 43%? Here’s your deep-dive into the DNA of a biotech rollercoaster—with humor, icons, and a whole lot of exome.
🚛 Heartland Express: Back Up the Truck Before It’s Too Late!
Insiders are buying, the CEO owns 32 million shares, and the balance sheet's tightening up—even as losses persist. Is Heartland Express (HTLD) stuck in reverse or about to hit the gas?
🏰 KKR: Kingdom of Capital and... Real Estate, Biotech, Semiconductors, Grocery Stores, and Also Probably Your Mom’s Soup Recipe?
KKR isn’t just a firm—it’s a capital empire. And when several directors shell out millions of dollars for shares, you take notice. From fee-rich earnings to a stake in just about everything that breathes profit, here's why KKR might deserve a seat in your portfolio—and your heart. 💼❤️ Director Robert Scully just bought big into KKR—and he’s not alone. With $664B in assets under management and a deal machine that never sleeps, KKR might just be the king of kings in capital. Here's our fun (and slightly ridiculous) take on whether it deserves a spot in your portfolio.